<p><strong>武田药品工业株式会社</strong>（TSE:4502）的全年业绩上周发布，现在是回顾其表现的好时机。整体结果是积极的——尽管收入为 4.5 万亿日元与分析师的预测一致，但武田药品交出了每股 122 日元的法定利润，略高于预期。结果公布后，分析师们更新了他们的盈利模型，了解他们是否认为公司的前景发生了重大变化，或者一切如常，将是很有意义的。因此，我们收集了最新的财报后法定共识估计，以查看明年可能会发生什么。</p>
<p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/874540-earnings-and-revenue-growth-1-dark-2/1778880783461?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/874540-earnings-and-revenue-growth-1-dark-2/1778880783461"/></p>
<p>TSE:4502 收益和收入增长 2026 年 5 月 15 日</p>
<p>在最新结果发布后，覆盖武田药品的 14 位分析师现在预测 2027 年的收入为 4.61 万亿日元。如果实现，这将比过去 12 个月的收入增长 2.4%。每股收益预计将增长 13%，达到 137 日元。在这份报告发布之前，分析师们曾预测 2027 年的收入为 4.59 万亿日元，每股收益（EPS）为 161 日元。分析师们似乎在最新结果后变得更加悲观。虽然收入预测没有变化，但每股收益的预期确实有所下调。</p>
<p>查看我们对武田药品的最新分析</p>
<p>可能会让人惊讶的是，分析师们的共识目标价基本保持在 6,124 日元，显然暗示预计收益的下降不会对估值产生太大影响。然而，过于关注单一目标价可能是不明智的，因为共识目标实际上是分析师目标价的平均值。因此，一些投资者喜欢查看估计范围，以了解对公司估值是否存在分歧意见。对武田药品的看法存在一些差异，最乐观的分析师将其估值为 7,800 日元，而最悲观的则为每股 4,900 日元。正如您所见，分析师们对该股票的未来并不完全一致，但估计范围仍然相对狭窄，这可能表明结果并非完全不可预测。</p>
<p>现在从更大的视角来看，我们可以通过将这些预测与过去的表现和行业增长预期进行比较来理解它们。我们要强调的是，武田药品的收入增长预计将放缓，预计到 2027 年底的年化增长率为 2.4%，远低于过去五年的历史年均增长率 7.0%。相比之下，行业内其他有分析师覆盖的公司预计年收入增长为 3.9%。考虑到增长放缓的预测，显然武田药品的增长也预计将低于其他行业参与者。</p>
<h2>结论</h2>
<p>最重要的是，分析师们下调了每股收益的预期，显示出在这些结果发布后情绪明显下降。幸运的是，分析师们也重新确认了他们的收入预期，表明其与预期一致。尽管我们的数据确实表明武田药品的收入预计将表现不及更广泛的行业。共识目标价没有实质性变化，表明最新估计并未对公司的内在价值产生重大影响。</p>
<p>考虑到这一点，我们不应急于对武田药品下结论。长期的盈利能力远比明年的利润更为重要。在 Simply Wall St，我们有一系列到 2029 年的武田药品分析师估计，您可以在我们的平台上免费查看。</p>
<p>话虽如此，仍然有必要考虑投资风险的潜在威胁。<strong>我们已识别出武田药品的 3 个警示信号</strong>，理解这些信号应成为您投资过程的一部分。</p>
<h3>估值复杂，但我们在这里为您简化。</h3>
<p>通过我们的详细分析，发现武田药品是否可能被低估或高估，分析内容包括 <strong>公允价值估计、潜在风险、股息、内部交易及其财务状况。</strong></p>
<p>访问免费分析</p>

4502

<p>武田药品工业株式会社报告每股法定利润为 122 日元，超出分析师预期，而收入与预测一致，达到 4.5 万亿日元。分析师预测到 2027 年收入将适度增长至 4.61 万亿日元，但已下调每股收益预期至 137 日元，反映出情绪的下降。共识目标价保持不变，为 6,124 日元，尽管与行业同行相比增长放缓，但仍显示出稳定的估值。分析师强调了三个投资者需要考虑的警示信号</p>

<p>The full-year results for <strong>Takeda Pharmaceutical Company Limited</strong> (TSE:4502) were released last week, making it a good time to revisit its performance. The result was positive overall - although revenues of JP¥4.5t were in line with what the analysts predicted, Takeda Pharmaceutical surprised by delivering a statutory profit of JP¥122 per share, modestly greater than expected. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.</p>
<div class="lb-trans"><p><strong>武田药品工业株式会社</strong>（TSE:4502）的全年业绩上周发布，现在是回顾其表现的好时机。整体结果是积极的——尽管收入为 4.5 万亿日元与分析师的预测一致，但武田药品交出了每股 122 日元的法定利润，略高于预期。结果公布后，分析师们更新了他们的盈利模型，了解他们是否认为公司的前景发生了重大变化，或者一切如常，将是很有意义的。因此，我们收集了最新的财报后法定共识估计，以查看明年可能会发生什么。</p>
</div><p>We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p>
<div class="lb-trans"><p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/874540-earnings-and-revenue-growth-1-dark-2/1778880783461" alt="" original-src="https://images.simplywall.st/asset/chart/874540-earnings-and-revenue-growth-1-dark-2/1778880783461"/></p>
<p>TSE:4502 Earnings and Revenue Growth May 15th 2026</p>
<div class="lb-trans"><p>TSE:4502 收益和收入增长 2026 年 5 月 15 日</p>
</div><p>After the latest results, the 14 analysts covering Takeda Pharmaceutical are now predicting revenues of JP¥4.61t in 2027. If met, this would reflect an okay 2.4% improvement in revenue compared to the last 12 months. Per-share earnings are expected to swell 13% to JP¥137. In the lead-up to this report, the analysts had been modelling revenues of JP¥4.59t and earnings per share (EPS) of JP¥161 in 2027. The analysts seem to have become more bearish following the latest results. While there were no changes to revenue forecasts, there was a real cut to EPS estimates.</p>
<div class="lb-trans"><p>在最新结果发布后，覆盖武田药品的 14 位分析师现在预测 2027 年的收入为 4.61 万亿日元。如果实现，这将比过去 12 个月的收入增长 2.4%。每股收益预计将增长 13%，达到 137 日元。在这份报告发布之前，分析师们曾预测 2027 年的收入为 4.59 万亿日元，每股收益（EPS）为 161 日元。分析师们似乎在最新结果后变得更加悲观。虽然收入预测没有变化，但每股收益的预期确实有所下调。</p>
</div><p>Check out our latest analysis for Takeda Pharmaceutical</p>
<div class="lb-trans"><p>查看我们对武田药品的最新分析</p>
</div><p>It might be a surprise to learn that the consensus price target was broadly unchanged at JP¥6,124, with the analysts clearly implying that the forecast decline in earnings is not expected to have much of an impact on valuation. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on Takeda Pharmaceutical, with the most bullish analyst valuing it at JP¥7,800 and the most bearish at JP¥4,900 per share. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.</p>
<div class="lb-trans"><p>可能会让人惊讶的是，分析师们的共识目标价基本保持在 6,124 日元，显然暗示预计收益的下降不会对估值产生太大影响。然而，过于关注单一目标价可能是不明智的，因为共识目标实际上是分析师目标价的平均值。因此，一些投资者喜欢查看估计范围，以了解对公司估值是否存在分歧意见。对武田药品的看法存在一些差异，最乐观的分析师将其估值为 7,800 日元，而最悲观的则为每股 4,900 日元。正如您所见，分析师们对该股票的未来并不完全一致，但估计范围仍然相对狭窄，这可能表明结果并非完全不可预测。</p>
</div><p>Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. We would highlight that Takeda Pharmaceutical's revenue growth is expected to slow, with the forecast 2.4% annualised growth rate until the end of 2027 being well below the historical 7.0% p.a. growth over the last five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 3.9% per year. Factoring in the forecast slowdown in growth, it seems obvious that Takeda Pharmaceutical is also expected to grow slower than other industry participants.</p>
<div class="lb-trans"><p>现在从更大的视角来看，我们可以通过将这些预测与过去的表现和行业增长预期进行比较来理解它们。我们要强调的是，武田药品的收入增长预计将放缓，预计到 2027 年底的年化增长率为 2.4%，远低于过去五年的历史年均增长率 7.0%。相比之下，行业内其他有分析师覆盖的公司预计年收入增长为 3.9%。考虑到增长放缓的预测，显然武田药品的增长也预计将低于其他行业参与者。</p>
</div><h2>The Bottom Line</h2>
<div class="lb-trans"><h2>结论</h2>
</div><p>The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Takeda Pharmaceutical's revenue is expected to perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.</p>
<div class="lb-trans"><p>最重要的是，分析师们下调了每股收益的预期，显示出在这些结果发布后情绪明显下降。幸运的是，分析师们也重新确认了他们的收入预期，表明其与预期一致。尽管我们的数据确实表明武田药品的收入预计将表现不及更广泛的行业。共识目标价没有实质性变化，表明最新估计并未对公司的内在价值产生重大影响。</p>
</div><p>With that in mind, we wouldn't be too quick to come to a conclusion on Takeda Pharmaceutical. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for Takeda Pharmaceutical going out to 2029, and you can see them free on our platform here..</p>
<div class="lb-trans"><p>考虑到这一点，我们不应急于对武田药品下结论。长期的盈利能力远比明年的利润更为重要。在 Simply Wall St，我们有一系列到 2029 年的武田药品分析师估计，您可以在我们的平台上免费查看。</p>
</div><p>That said, it's still necessary to consider the ever-present spectre of investment risk. <strong>We've identified 3 warning signs</strong> with Takeda Pharmaceutical , and understanding these should be part of your investment process.</p>
<div class="lb-trans"><p>话虽如此，仍然有必要考虑投资风险的潜在威胁。<strong>我们已识别出武田药品的 3 个警示信号</strong>，理解这些信号应成为您投资过程的一部分。</p>
</div><h3>Valuation is complex, but we're here to simplify it.</h3>
<div class="lb-trans"><h3>估值复杂，但我们在这里为您简化。</h3>
</div><p>Discover if Takeda Pharmaceutical might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p>
<div class="lb-trans"><p>通过我们的详细分析，发现武田药品是否可能被低估或高估，分析内容包括 <strong>公允价值估计、潜在风险、股息、内部交易及其财务状况。</strong></p>
</div><p>Access Free Analysis</p>
<div class="lb-trans"><p>访问免费分析</p>
</div>

武田药品工业株式会社刚刚录得每股收益超预期 8.6%：以下是分析师的后续预测